Physician profile
Jaime D Cunningham
NPI 1285053678
$1,623.78
in general payments reported to CMS, 2019-2025
30 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $208 · 2022: $495 · 2023: $293 · 2024: $276 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $902 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $902.02 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $391.57 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $208.62 | 2021-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $141.17 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $114.15 | 2022-2023 | |
| Pfizer INC. | $89.94 | 2022-2025 | |
| Abbott Laboratories | $70.11 | 2022-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $54.39 | 2021-2024 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $48.35 | 2022 | |
| Radius Health, INC. | $46.40 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $41.09 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $39.76 | 2021-2025 | Farxiga |
| Xeris Pharmaceuticals, INC. | $37.53 | 2021-2022 | |
| Inspire Medical Systems, INC. | $35.44 | 2025 | Inspire |
| Boston Scientific Corporation | $28.28 | 2025 | Watchman Access System |
| Esperion Therapeutics, INC. | $24.25 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $22.50 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.67 | 2021 | |
| Endo USA, INC. | $20.33 | 2024 | Xiaflex |
| Lundbeck LLC | $20.09 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Dexcom, INC. | $18.60 | 2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $17.06 | 2022 | |
| Eisai INC. | $15.88 | 2021 | |
| Abiomed | $15.84 | 2024 | Impella |
| Philips North America LLC | $15.25 | 2024 | (Ck6) Holter |
| Actelion Pharmaceuticals US, INC. | $14.38 | 2024 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $14.18 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.01 | 2023 | |
| Janssen Pharmaceuticals, INC | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.